Phaseline

Targets › MAP3K8

MAP3K8 (Mitogen-activated protein kinase kinase kinase 8): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Jan 2027.

Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the pro-inflammatory cytokine TNF (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. (UniProt, P41279)

Open in Phaseline: the race on MAP3K8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesTilpisertib
Mitogen-activated protein kinase kinase kinase 8 inhibitor
MAP3K8Phase 2Ulcerative ColitisJan 2027

Conditions

Ulcerative Colitis (1)

Modalities

small molecule (1)

Companies

Gilead Sciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.